CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma.

CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...

This year saw several advancements across medicine, space technology, and AI that extend our knowledge in consequential ways.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

IT has been a truly wonderful year for medicine with pioneering innovative research leading to numerous life-saving ...

It also gained prominence earlier this year through its CASGEVY treatment which became the world’s first gene-editing-based treatment for Sickle Cell Disease. However, the latter half of 2024 ...

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...